RxDoctor Payments Data

Jamie Deputy, APRN

Psychiatric/Mental Health · Virginia Beach, VANPI 1053851436

Payments from drug & device makers

$4,797in general payments, 2019–2025

Across 260 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$944
  • AbbVie$897
  • Johnson & Johnson$461
  • Neurocrine Biosciences, Inc.$435
  • Lundbeck LLC$364
  • Supernus Pharmaceuticals, Inc.$338
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,75099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,797 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$5,725
Medicare patients
36
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LatudaLurasidone Hcl13$51,486
VraylarCariprazine Hcl34$49,737
Wellbutrin XlBupropion Hcl11$46,928
Paliperidone ErPaliperidone51$14,450
Aripiprazole27$2,030
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$1,649
Atomoxetine Hcl11$1,190
Venlafaxine Hcl ErVenlafaxine Hcl71$903
Vilazodone Hcl16$585
Citalopram HbrCitalopram Hydrobromide22$516
Fluphenazine Hcl24$507
Ziprasidone Hcl13$431
Trazodone Hcl88$397
Quetiapine Fumarate30$392
Quetiapine Fumarate ErQuetiapine Fumarate11$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$897$49,73734 claims
Almatica Pharma LLCSertraline Hcl$43$12116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →